论文部分内容阅读
目的:探讨血清六项肿瘤标志物(TM)联合检测对恶性肿瘤诊断的价值和意义。方法:对425例恶性肿瘤患者血清六项肿瘤标志物:β2-微球蛋白(β2-MG),糖蛋白CA153、CA125、CA199,甲胎蛋白(AFP),癌胚抗原(CEA)进行检测,并对结果进行统计分析。结果:血清六项肿瘤标志物联合检测的阳性率明显高于单项检测,阳性率随联检项目的增多而升高。在各肿瘤病种中,六项肿瘤标志物联检阳性率:肝癌组为92.9%(最高),胰腺癌组为92.3%,肺癌组为75.6%,卵巢癌组为72.7%,肠癌组为63.8%,喉癌组为60%,胃癌组为58.8%,食道癌为51.5%。结论:六项TM的联合检测提高了肿瘤检出率,为肿瘤的早期诊断提供可靠依据。
Objective: To investigate the value and significance of combined detection of six serum tumor markers (TM) in the diagnosis of malignant tumors. Methods: The serum tumor markers of 425 malignant tumor patients were detected: β2-MG, glycoproteins CA153, CA125, CA199, AFP and CEA. And statistical analysis of the results. Results: The positive rate of the combined detection of six tumor markers in serum was significantly higher than that of single detection, and the positive rate increased with the increase of the joint inspection items. The positive rates of six tumor markers were 92.9% (highest) in liver cancer group, 92.3% in pancreatic cancer group, 75.6% in lung cancer group, 72.7% in ovarian cancer group and 63.8 %, 60% in laryngocarcinoma group, 58.8% in gastric cancer group and 51.5% in esophageal cancer group. Conclusion: The combined detection of six TM improves the detection rate of tumor, and provides a reliable basis for the early diagnosis of tumor.